Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Tcheng

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Texas Heart Institute Journal|May 5, 1998
Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapyJ E Tcheng
American Heart Journal|September 1, 1995
Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agentsJ E Tcheng
American Heart Journal|January 29, 2000
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatmentJ E Tcheng
The American Journal of Cardiology|August 18, 1997
Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ E Tcheng
The American Journal of Cardiology|June 5, 1999
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatmentJ E Tcheng
The American Journal of Cardiology|August 14, 1996
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspectiveJ E Tcheng
Thrombosis and Haemostasis|July 1, 1997
Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiologyJ E Tcheng
American Heart Journal|September 29, 1999
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromesJ E Tcheng
The Journal of Invasive Cardiology|December 9, 1993
Dosing and administration of ReoPro (c7E3 Fab)J E Tcheng
Seminars in Interventional Cardiology : SIIC|June 1, 1996
Saline infusion in excimer laser coronary angioplastyJ E Tcheng
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Texas Heart Institute Journal|May 5, 1998
Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapyJ E Tcheng
American Heart Journal|September 1, 1995
Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agentsJ E Tcheng
American Heart Journal|January 29, 2000
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatmentJ E Tcheng
The American Journal of Cardiology|August 18, 1997
Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ E Tcheng
The American Journal of Cardiology|June 5, 1999
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatmentJ E Tcheng
The American Journal of Cardiology|August 14, 1996
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspectiveJ E Tcheng
Thrombosis and Haemostasis|July 1, 1997
Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiologyJ E Tcheng
American Heart Journal|September 29, 1999
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromesJ E Tcheng
The Journal of Invasive Cardiology|December 9, 1993
Dosing and administration of ReoPro (c7E3 Fab)J E Tcheng
Seminars in Interventional Cardiology : SIIC|June 1, 1996
Saline infusion in excimer laser coronary angioplastyJ E Tcheng
Pageof 10